MiMedx GroupMDXG
MDXG
About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Employees: 837
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 23
67% more capital invested
Capital invested by funds: $581M [Q3] → $970M (+$389M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
15% more call options, than puts
Call options by funds: $610K | Put options by funds: $529K
9% more funds holding
Funds holding: 193 [Q3] → 210 (+17) [Q4]
1.65% more ownership
Funds ownership: 66.99% [Q3] → 68.64% (+1.65%) [Q4]
22% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 65
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
73%
upside
Avg. target
$13
73%
upside
High target
$13
73%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target | 73%upside $13 | Overweight Reiterated | 27 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference.
Neutral
Seeking Alpha
1 month ago
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call.
Positive
Zacks Investment Research
1 month ago
MiMedx (MDXG) Q4 Earnings Meet Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2024.
Positive
Zacks Investment Research
3 months ago
MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Positive
Zacks Investment Research
3 months ago
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
3 months ago
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Positive
Zacks Investment Research
4 months ago
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
4 months ago
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Neutral
GlobeNewsWire
4 months ago
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Charts implemented using Lightweight Charts™